New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTEPD, GCI, JNPR, LFL, MMYT, RBC, TEVA, RIGOn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Check below for free stories on EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:57 EDTLFLDeutsche Bank to hold a conference
Global Emerging Markets 1:1 Conference to be held in New York on September 3-5.
13:27 EDTJNPRAT&T to hold a conference
16th Annual AT&T Cyber Security Conference will be held in New York on September 3-4 with webcast availability on September 4 at 9 am; Webcast Link
13:20 EDTJNPRCitigroup to hold a conference
Global Technology Conference to be held in New York on September 2-4.
August 28, 2014
11:22 EDTTEVAMylan ANDA for three times per week generic Copaxone accepted by FDA for filing
Mylan (MYL) announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. This product is the generic version of Teva's (TEVA) Copaxone 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval. Copaxone 40 mg/mL had U.S. sales of approximately $411.5M for the 12 months ending June 30, 2014, according to IMS Health.
07:21 EDTTEVATeva recalls batch of generic Parkinson's drug in U.S., Globes reports
Subscribe for More Information
August 27, 2014
10:02 EDTRIGActive equity options trading on open
Subscribe for More Information
August 26, 2014
09:51 EDTRIGOn The Fly: Analyst Initiation Summary
Cray (CRAY) initiated with a Buy at Stifel... Enphase Energy (ENPH) initiated with a Buy at Needham... FCB Financial (FCB) initiated with a Buy at UBS... FCB Financial initiated with an Overweight at JPMorgan... Goldman Sachs (GS) initiated with a Buy at MKM Partners... HealthEquity (HQY) initiated with a Neutral at RW Bair... Mobileye (MBLY) initiated with a Buy at Deutsche Bank... Mobileye initiated with a Neutral at Goldman... Mobileye initiated with a Neutral at RW Baird... Mobileye initiated with an Overweight at Barclays... RAIT Financial (RAS) initiated with an Outperform at JMP Securities... SunEdison (SUNE) initiated with an Outperform at FBR Capital... Mobileye initiated with an Outperform at Raymond James... Transocean Partners (RIG) initiated with an Overweight at Morgan Stanley... GT Advanced (GTAT) coverage resumed with an Overweight at Piper Jaffray... LinkedIn (LNKD) initiated with an Overweight at First Analysis... CSC (CSC) initiated with a Sector Perform at RBC Capital... United Natural Foods (UNFI) initiated with an Overweight at Stephens.
August 25, 2014
10:00 EDTRIGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
August 21, 2014
15:16 EDTTEVADEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
August 20, 2014
10:04 EDTRBCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BHP Billiton (BHP) downgraded to Underperform from Neutral at Credit Suisse... GT Advanced (GTAT) downgraded to Underperform from Outperform at CLSA... Hertz (HTZ) downgraded to Hold from Buy at Deutsche Bank... IDEXX (IDXX) downgraded to Sell from Neutral at Northcoast... Prestige Brands (PBH) downgraded to Neutral from Buy at Sidoti... Real Goods Solar (RGSE) downgraded to Neutral from Buy at Roth Capital... Regal-Beloit (RBC) downgraded to Neutral from Buy at Longbow... SunCoke Energy (SXC) downgraded to Neutral from Outperform at Credit Suisse... Tidewater (TDW) downgraded to Market Perform from Outperform at Clarkson Capital.
08:27 EDTRIGTransocean management to meet with Jefferies
Subscribe for More Information
07:17 EDTRBCRegal-Beloit downgraded to Neutral from Buy at Longbow
Subscribe for More Information
August 19, 2014
11:05 EDTJNPRImperva seen as takeover candidate under new CEO
Subscribe for More Information
08:42 EDTJNPRImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
05:11 EDTTEVAGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
10:06 EDTTEVALannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
08:50 EDTTEVATeva management to meet with JPMorgan
Meeting to be held in Boston on August 20 hosted by JPMorgan.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use